ESC Highlights 2024





ESC 2024 Highlights: Live Webcast



Milan Gupta,
MD, FRCPC, FCCS, CPC(HC)
Assistant Professor, Department
of Medicine, University of Toronto
Medical Director, Canadian
Collaborative Research Network
Brampton, ON



Narendra Singh,
MD, FRCPC, FCCS, FACC, FAHA
Director, NSC Cardiology
Clinical Assistant Professor,
Medical College of Georgia at
Augusta University and Mercer
University
Atlanta, GA

This program will cover the key clinical trial findings and their implications from ESC 2024. This program is intended for cardiovascular specialists and primary care physicians.

Discussion Topics:

- HELIOS-B Vutrisiran for transthyretin cardiomyopathy
- RESHAPE-HF2 and MATTERHORN The role of transcatheter mitral valve repair in patients with heart failure
- OCEANIC-AF How does the factor XI inhibitor asundexian compare vs. apixaban in AF?
- FINEARTS-HF What is the role of finerenone in HFpEF?
- AZALEA-TIMI 71 Factor XI inhibition and peri-procedural bleeding

Learning Objectives:

Following participation in this program, participants will be able to:

- Identify the clinical implications of the new data presented at ESC 2024
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice

This program was developed by CCRN and received an unrestricted educational grant from Alnylam Pharmaceuticals, Bayer Canada and Anthos Therapeutics.





